Real-World Evidence Solutions Market: Size, Share & Trends

Meticulous Research^®—a leading global market research company, published a research report titled,'Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS) End User - Global Forecast to 2031’.

The global RWE solutions market was valued at $2.62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031. The increasing prevalence of chronic illnesses, drug development delays and the resulting rise in development costs, the growing emphasis on personalized healthcare, the move toward value-based care, and the expanding use of real-world evidence solutions in drug development and commercialization are the main factors propelling the growth of the real-world evidence solutions market.

Key Players:

The key players operating in the global real-world evidence solutions market are IQVIA Holdings Inc. (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Revvity, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and HealthVerity, Inc. (U.S.).

Key Drivers of Market Growth:

RWE solutions are increasingly vital as chronic diseases become more prevalent globally and drug development faces escalating costs and longer timelines. Healthcare organizations and pharmaceutical companies are in a race to deliver new therapies at a lower cost and within shorter development cycles. This pressure is compounded by the market’s shift towards personalized medicine, value-based care models, and regulatory frameworks that favor data-backed decision-making.

Delays in traditional drug development and increased risks are driving RWE adoption, with companies employing RWD to improve clinical trial efficiency, assess drug usage post-marketing, and support regulatory submissions. Emerging economies offer further expansion opportunities, as governments invest in health data initiatives and adopt RWE for population health management and evidence-based medicine.

AI, Data Integration, and Analytics: Revenue Impact:

Technological advances, particularly in AI-driven analytics and machine learning, are now at the heart of RWE’s revenue forecasts and industry excitement. AI platforms process vast volumes of real-world data from patient registries, electronic health records, insurance claims, and wearable devices, facilitating anomaly detection, data standardization, and quality assurance. These enhancements:

• Accelerate drug discovery by rapidly identifying patterns and treatment outcomes in large datasets, cutting both timelines and operational costs for pharma and biotech companies.
• Enable personalized healthcare by segmenting patients and tailoring therapeutics based on real-world insights about effectiveness, safety, and adherence.
• Expand the scope of clinical and regulatory evidence available, transforming decision-making from R&D through to commercialization.

Consulting and analytics services are also forecast to grow rapidly, at a CAGR of 15.2% over the forecast period, due to the increasing complexity of healthcare data and the demand for specialized study design, protocol development, and clinical reporting.

Regional Growth Leaders in RWE Solutions:

North America’s dominance stems from advanced healthcare infrastructure, the proliferation of electronic datasets, supportive regulatory guidelines, and numerous established market players. The U.S. FDA’s adoption of RWE in regulatory processes, including post-market safety monitoring, further stimulates regional growth.

Asia-Pacific is set to register the highest CAGR at 11.2%, propelled by initiatives such as Japan’s “Rational Medicine” program, which promotes patient-centric and evidence-based healthcare delivery. Rising investment, supportive government policies, and the integration of RWE into healthcare systems in countries like China, Japan, and Taiwan signal tremendous potential for vendors targeting this market

Competitive Landscape and Future Outlook:

The competitive environment is marked by leading players such as IQVIA Holdings, Elevance Health, ICON plc, Cognizant Technology Solutions, Thermo Fisher Scientific, Oracle, SAS, Parexel, and others who are expanding their footprints and refining RWE offerings. The increasing importance of large diverse datasets – projected to constitute 53% of the market share in 2024 – highlights the market’s pivot toward outcomes-based and personalized models of care.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954

Key questions answered in the report-

• Which are the high-growth market segments in terms of component, application, end user, and region/country?
• What was the historical market size for the RWE solutions market globally?
• What are the market forecasts and estimates for the period 2024–2031?
• What are the major drivers, restraints, challenges, opportunities, and trends in the global RWE solutions market?

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research